Monday, July 30, 2007

Talecris Goes for Initial Public Offering

Hey Alpha-1 Community!

Hold onto to your hats. The producer of Prolastin, an augmentation therapy for Alpha-1 lung disease, is going public. Hot of the presses...

Talecris Biotherapeutics (TLCR) Files $1 Billion IPO
07-30-2007 09:06:31 AM

Talecris Biotherapeutics Holdings (Nasdaq: TLCR) has filed a registration statement with the SEC for an initial public offering of its common stock. The Company intends to apply to list its common units on the Nasdaq under the symbol “TLCR.” The proposed maximum aggregate offering price is $1 billion.

The offering is being made through Morgan Stanley, Goldman, Sachs & Co. and JPMorgan.

Talecris Biotherapeutics is a biopharmaceutical company that is one of the largest producers and marketers of plasma-derived protein therapies in the world. Talecris develops, produces, markets and distributes therapies that extend and enhance the lives of people suffering from chronic and acute, often life-threatening, conditions, such as immune deficiency disorders, alpha-1 antitrypsin (AAT) deficiency, infectious diseases, hemophilia and severe burns.

No comments: